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flecting real-life clinical practice based on structured interviews with experts.
METHODS: Six experts in the field of schizophrenia from different treatment
settings and regions in Germany were consulted. Structured interviews about
the treatment patterns and costs in selected outpatient and inpatient treatment
areas, e.g. psychiatrists, occupational therapists, day care units and acute psy-
chiatric wards, were conducted. Costs were assessed from the perspective of the
statutory health insurance. The assessment was divided into stable and relaps-
ing schizophrenic patients. Costs for the management of frequent side effects
were considered. RESULTS: The proportion of stable patients with schizophre-
nia was assessed to be 80% in Germany. Stable patients were estimated to have
1.5 psychiatrist contacts per quarter and relapsing patients were assessed to
have 6-8 contacts per quarter. Psychiatrist costs per quarter are varying be-
tween different regions in Germany, e.g. costs in Bavaria were €92 in 2011.
Inpatient costs per day in acute psychiatric wards are varying between €206 in
Baden-Württemberg and €244 in Saarland. CONCLUSIONS: The results of the
structured expert interviews will be used as input for cost-effectiveness models
in schizophrenia. In further studies the results should be verified in real-life
clinical practice.
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OBJECTIVES: Only few people with severe mental illness are able to obtain paid
work. Individual placement and support (IPS) is a vocational rehabilitation inter-
vention aimed at assisting people with severe mental illness in finding competitive
employment. This study assessed the balance between costs and outcomes of IPS
compared to regular vocational rehabilitation in people with severe mental illness
in the Netherlands. METHODS: An economic evaluation was conducted alongside
a multicenter RCT with a follow-up of 30 months. In total 151 people with severe
mental illness were randomly assigned to IPS or regular vocational rehabilitation-
(RVR). The primary outcome measure of the cost-effectiveness analysis was the
percentage of people with at least one day of paid work during the study. The
economic evaluation was conducted from a societal perspective. Costs and out-
comes were prospectively assessed during 30 months. The expectation maximisa-
tion algorithm with a bootstrap approach was applied to deal with missing cost
data. RESULTS: The percentage of people with paid work during the study was
significantly higher in the IPS group (44% versus 25% in RVR). There were no differ-
ences between groups in quality of life. Mean total costs were €57,285 in the IPS
group and €43,819 in the RVR group. Cost types that contributed considerably to the
total costs were related to hospital admissions, sheltered accommodations, and
informal care. The calculated incremental cost-effectiveness ratio was €1,084 per
percent of people with paid work gained. CONCLUSIONS: The study demonstrated
that IPS was associated with higher costs and better (work-related) outcomes in
people with severe mental illness. Decision makers will eventually have to decide
whether the described gains associated with IPS are worth the additional costs.
Generalizing current results to other countries may only be possible after carefully
comparing the various components of each health care system concerned.
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OBJECTIVES: Metabolic syndrome (MetS) is a medical condition that may arise
during exposure to antipsychotics and carries with it an increased risk of diabetes
and cardiovascular disease (CVD). Asenapine is the first tetracyclic antipsychotic to
treat manic episodes of Bipolar I Disorder (BD- I). In a head-to-head non-inferiority
trial versus olanzapine, post-hoc analyses illustrate the higher incidence of devel-
oping MetS with olanzapine than with asenapine, already after 12 weeks of treat-
ment. The aim of this study was to assess the cost-effectiveness of asenapine in the
treatment of BD-I manic episodes compared to atypical antipsychotics with a focus
on the long-term consequences of MetS over lifetime horizon. METHODS: A
Markov health-state cohort model was developed. Because similar efficacy in treat-
ing manic episodes was demonstrated in active controlled non-inferiority clinical
trial vs. olanzapine and through indirect comparisons with quetiapine and arip-
iprazole, only the consequences of MetS were considered for this model. The risks
of developing MetS after 12 weeks of treatment were derived from randomized
clinical trials. The subsequent risks of developing diabetes or cardiovascular dis-
ease were based on previously published risk models. The perspective of the UK
National Health Service (NHS) was applied and a lifetime horizon adopted. Deter-
ministic and probabilistic sensitivity analyses were conducted. RESULTS: Asenap-
ine dominates (more effective and less expensive) olanzapine, quetiapine and arip-
iprazole over lifetime horizon. Compared to treatment with generic olanzapine,
and branded aripiprazole and quetiapine, asenapine was associated with incre-
mental total costs of -£121, -£312 and -£560 respectively. Asenapine was associated
with Quality-Adjusted Life Year gains of 0.0569 compared to olanzapine and que-
tiapine, and 0.0038 compared to aripriprazole. CONCLUSIONS: The significant
lower incidence of developing MetS associated with asenapine compared to olan-
zapine, aripriprazole and quetiapine is associated with a lower incidence of diabe-
tes and CVD that results in lower subsequent treatment costs and improved mor-
bidity.
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OBJECTIVES: Acute agitation is a transient syndrome characterized by increase in
verbal and physical behavior, which results in aggression. In order to diminish the
risk of damage for both, caregivers and patients, fast response drugs are required.
The study is aimed to estimate the pharmacoeconomic profile of intramuscular
injections of haloperidol 5mg, olanzapine 10mg and ziprasidone 20mg for acute
agitation episodes associated with schizophrenia, from the perspective of a Mexi-
can public health institution. METHODS: A discrete event simulation model was
developed. The measure of effectiveness was the average time in which patients
reach control50%, regarding baseline level in the Overt Aggression Scales, with a
time horizon of 12 hours. Clinical efficacy was extracted from published literature.
A panel of experienced psychiatrists (n12) was used to estimate the medical
resource use profile. The model assesses direct medical costs (2012 US$) such as
drugs, specialist’s visits, laboratory tests and management of adverse events. The
results are reported in terms of ICER. Deterministic and probabilistic sensitivity
analyses were performed. RESULTS: The cost per patient for ziprasidone was $693,
it represents $198.6 and $64.6 less than the cost of haloperidol and olanzapine,
respectively. Differences in costs were driven by less specialist’s visits with ziprasi-
done and high incidence of akathisia and dystonia with haloperidol. The effective-
ness measure was accomplished by ziprasidone, olanzapine and haloperidol at
1.55h, 1.48h and 1.74h, respectively. Both ziprasidone and olanzapine dominated
haloperidol. Results were robust to changes up to10% in the acquisition cost of ziprasi-
done. Inprobabilisticsensitivityanalysis, resultswereconsistentwithbasecase,although
differences between ziprasidone and olanzapine were slighter.CONCLUSIONS: In com-
parison to olanzapine and haloperidol, ziprasidone is associated to the lowest costs
in the treatment of acute agitation episodes in schizophrenic patients in the Mex-
ican setting, as well as better clinical performance than haloperidol.
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OBJECTIVES: We conducted a pharmacoeconomic analysis to determine the cost-
effectiveness of atypical antipsychotic long acting treatments in Croatia.
METHODS: A 1-year decision-analytic framework modeled drug use in chronic
schizophrenia. We determined the average direct cost to the Croatian Institute for
Health Insurance of using treatment pathways that includes depot formulations of
paliperidone (PP-LAI), risperidone (RIS-LAI) or olanzapine (OLZ-LAI) long acting
treatments. The decision tree was populated with guidance from an expert panel
along with literature-derived clinical rates. Costs were obtained from published
lists and adjusted to 2012 euros using the Croatian consumer price index. Clinical
outcomes included quality-adjusted life-years (QALYs), hospitalization rates,
emergency room treatment rates, and relapse days. The outcome of interest was
the incremental cost/QALY gained. RESULTS: Total direct costs to treat one patient
for one year were €4958 for PP-LAI, €5117 for RIS-LAI, and €6429 for OLZ-LAI. Re-
spective QALYs were 0.817, 0.805 and 0.812. PP-LAI dominated the other choices as
it had a lower cost and higher QALY score. PP-LAI was associated with 34.5 relapse
days, 0.252 hospitalizations and 0.127 emergency room visits; OLZ-LAI had 38.4
relapse days, 0.280 hospitalizations and 0.142 emergency room visits; RIS-LAI had
41.1 relapse days, 0.305 hospitalizations and 0.146 emergency room visits. Results
were sensitive against RIS-LAI with respect to drug costs (i.e., if PP-LAI cost in-
creased by 10% or RIS-LAI decreased by 14%) and to OLZ-LAI (i.e., a 10% change for
either drug) with respect to adherence rates. Overall, results were generally robust;
PP-LAI dominated OLZ-LAI in 72.2% of 10,000 Monte Carlo simulations and domi-
nated RIS-LAI in 87.8%. CONCLUSIONS: PP-LAI was the cost-effective choice which
dominated the others for treating chronic schizophrenia in Croatia. Using depot
paliperidon would reduce the overall costs of caring for SCH patients.
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OBJECTIVES: We determined the cost-effectiveness of long-acting antipsychotic
(LAI) drugs paliperidone palmitate (PP-LAI), olanzapine pamoate (OLZ-LAI) and ris-
peridone (RIS-LAI) for chronic schizophrenia. METHODS: We adapted a decision
tree analysis from Norway for the Finnish National Health Service. Country-spe-
cific data were sought from the literature and public documents, guided by clinical
experts. Costs of health services and products were retrieved from literature
sources and current price lists. We estimated average costs for treating patients
with each LAI for one year, average remission days, rates of hospitalization and
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emergency room visits, and quality-adjusted life-years.RESULTS: PP-LAI was dom-
inant. It cost €10,169/patient; outcomes included 330.1 days in remission, 25% were
hospitalized, 12% visited emergency rooms and 0.845 QALY. OLZ-LAI costs were
€11,589; patients experienced 326.8 remission days and 0.844 QALY; 27% were hos-
pitalized and 14% visited emergency rooms. RIS-LAI costs were €12,091; patients
experienced 323.8 remission days and 0.836 QALY; 30% were hospitalized and 14%
visited emergency rooms. For all products, costs were approximately 35% due to
drugs, 48% hospitalization, and the remainder due to medical care. The analysis
was robust against most variations in input values; adherence rates were sensitive.
PP-LAI was dominant over OLZ-LAI and RIS-LAI in 50% and 73% of simulations,
respectively. CONCLUSIONS: In Finland, PP-LAI dominated the other LAIs as it was
associated with a lower cost and better clinical outcomes.
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OBJECTIVES: To perform economic evaluation of paliperidone palmitate suspen-
sion for injection (PPI) compared to risperidone long acting injection (RLAI) for the
treatment of schizophrenia from Russian health care system point of view.
METHODS: Direct medical costs of treating schizophrenia with PPI and RLAI for 1
year were calculated in an Excel model. The model was based on simulation of rate
of relapse taking into account the expected adherence to treatment. The key pa-
rameters of the model were derived from the systematic review of the RCTs results,
e-STAR observational study (local data for Russia) and expert panel opinions. Ad-
herence simulation was based on the assumption that reduced number of injec-
tions will decrease number of patients giving up treatment and thus decrease
probability of relapse. Direct costs of treatment included hospitalization for the
relapse, outpatient care visits, and the cost of RLAI and PPI Sensitivity analysis to
the variations of key parameters was made. RESULTS: Analysis of the results of
RCTs has not shown superiority of RLAI-based treatment efficacy or safety over
PPI-based treatment. The only possible advantage is increased adherence rate due
to reduced number of injections per month. If adherence increases from 75.7% to
82.3% the costs of medical care in a hypothetical cohort of patients with schizo-
phrenia is less for PPI 6.36 bln USD vs 6.45 bln USD in case of RLAI (per year). Thus
difference in costs in a hypothetical cohort of patients with schizophrenia is 87,881
USD, or 87.88 USD per patient. Variation in the level of non-adherence to treatment
did not influence the results but the economic advantage of PPI disappears when its
price increases by1.5% from baseline. CONCLUSIONS: PPI may constitute a cost-
saving treatment option for patients with schizophrenia if its price is no more than
6.62 USD per mg.
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OBJECTIVES: To assess the cost-effectiveness of escitalopram as first line treat-
ment of MDD in Belgium. METHODS: The model structure was based on a decision
tree developed by the Swedish Dental and Pharmaceutical Benefits Agency (TLV).
Comparators included citalopram, fluoxetine, paroxetine, sertraline, duloxetine,
venlafaxine and mirtazapine. In the model, patients not achieving remission or
relapsing on the assessed treatment moved to a second therapeutic step (titration,
switch, add-on or transfer to a specialist). In case of failure in the second step or
following a suicide attempt, patients were assumed to be referred to secondary
care. The time horizon was one year and the analysis was conducted from the
NIHDI (national health insurance) and societal perspectives. Remission rates were
obtained from a network meta-analysis published by the TLV and other model
parameters were derived from the published literature and experts’ opinion. To
reflect local practices, a recent Belgian survey of 97 GPs (general practitioners) on
the management of MDD was used. The effect of uncertainty in model parameters
was estimated through scenario analyses and a probabilistic sensitivity analysis
(PSA). RESULTS: In the base case analysis, escitalopram was identified as the opti-
mal strategy: it dominated all other treatments except venlafaxine from the NIHDI
perspective, against which it was cost-effective with an incremental cost-effective-
ness ratio of €6,351 per quality-adjusted-life-year (QALY). Due to the high cost of
absenteeism, escitalopram dominated all other strategies from the societal per-
spective. At a threshold of €30,000 per QALYs from the NIHDI perspective, the PSA
showed that, in comparison to the other drugs, escitalopram had a probability
between 61% (vs. venlafaxine) and 100% (vs fluoxetine) to be identified as the op-
timal strategy. CONCLUSIONS: Escitalopram was identified as the optimal strategy
from the NIHDI and societal perspectives. This study investigated ways to present
sensitivity analyses while comparing multiple strategies.
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OBJECTIVES: To estimate cost-effectiveness of different (7 drugs) peroral atypi-
cal antipsychotics (AAP) vs haloperidol (H) for the treatment of schizophrenia.
METHODS: Cost-effectiveness analysis of AAP compared to H for schizophrenia
treatment was performed. A mathematical model based on simulation of treat-
ment outcomes in hypothetical cohort of patients was developed. Key parame-
ters of the model were determined using systematic review of the RCTs results
(improvement in clinical and functional status as measured by the PANSS and
CGI, frequency of relapse, adverse events), e-STAR observational study (local
data for Russia), epidemiological data and expert panel opinions. For each op-
tion direct costs of treatment were considered: hospitalization and outpatient
care, and the cost of medications for AAP- and H-based treatment. ICER (cost of
a day without exacerbation of the disease) for each AAP was calculated vs H.
RESULTS: According to published trials the treatment of schizophrenia in the
AAP-based therapy was associated with a significant improvement in PANSS
and CGI, decreased rate of relapse and adverse events compared to H-based
treatment. Analysis of the results of RCTs has not shown superiority of any
certain drug inside the AAP group. In case of application of AAP-based therapy
hospitalization rate decreases by 38% compared to H-based treatment but the
total cost of treatment remains lower for H. Depending on the drug ICERaap for
AAP vs H varies from 4,202 USD to 18,157 USD per day without exacerbation of
the disease. In group AAP paliperidone has the lowest ICER vs H - 4202 USD.
CONCLUSIONS: Results of the study suggest that AAP-are more efficacious com-
pared to H, the total cost of treatment remains lower for H. In-group AAP paliperi-
done is more cost-effective.
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OBJECTIVES: Depression has a lifetime prevalence of 10–25% among women and
5–12% among men. Selective serotonin reuptake inhibitors (SSRIs) are the most
used and the most cost effective treatment in long-term MDD. Since the introduc-
tion of generic SSRIs the costs of the branded drug have been questioned. The
objective of this study is to analyze the Cost-effectiveness of the most prescribed
SSRIs: sertraline, paroxetine, citalopram, that lost their patent, and escitalopram
that is still covered by a patent. METHODS: A decision analytic model was adapted
from TLV (Dental and Pharmaceutical Benefits Board, Sweden) in order to reflect
the current clinical practice in depression helped by a panel of Psychiatrists and
Health economists. Perspective used was the Lombardy Region Health Service and
the Time horizon was 12 months. Several scenario simulations, one way Sensitivity
analyses and Monte Carlo simulations have been performed in order to test the
robustness of the model. RESULTS: Base case scenario showed an ICER of escita-
lopram vs. sertraline of € 4.395. All the tests showed that citalopram and paroxetine
are dominated. One way Sensitivity analyses and tests were performed resulting in
ICER variation from € 135 to € 18.000, nevertheless Monte Carlo simulations have
shown an ICER stabilized at the mean value of around 4.000 euro confirming the
base case scenario. CONCLUSIONS: ICER represents the additional cost due to a
new technology related to its additional benefits. ICER has to be compared with a
meaningful threshold value under which a technology may be considered cost-
effective. Many agencies have studied this threshold. PBAC (Australia) propose €
25K, NICE (UK) propose € 35K. Comparing our base case scenario and also the ICER
ranges that came from the Sensitivity analyses (One way and multivariate) with
these thresholds escitalopram should be accepted as a cost-effective treatment for
MDD.
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OBJECTIVES: Several studies have demonstrated that Risperidone Long-Acting
Injectable (RLAI) reduces psychotic relapses, hospitalization and resources used
among schizophrenic patients with poor adherence to oral medication. How-
ever, the magnitude of such reductions depends upon the baseline relapse rate.
This study is aimed at identifying the thresholds of relapse risk at which RLAI is
cost-effective, compared to Oral Olanzapine (OO), Oral Quetiapine (OQ) and
Haloperidol Decanoate (HD). METHODS: A Markov model was developed to sim-
ulate the natural history of schizophrenia for patients who have poor adherence
and high risk of relapse with oral medication. The strategies compared were
starting treatment with RLAI, OO, OQ or HD. Relapse probabilities, adherence
levels, side effects and treatment switching were derived from long-term obser-
vational data. Resource use and costs were obtained from Mexican public insti-
tutions. Patients transit through different health states in the model on a
monthly basis over a 10-year time horizon. Incremental cost and effectiveness
outcomes were discounted at 3% annually. RESULTS: In patients with Baseline
Annual Relapse Rate (BARR) equal or greater than 72.5%, RLAI is the most effec-
tive and less costly treatment (cost-saving) if effectiveness is measured in terms
of QALYs or relapses averted. In this case, RLAI produces 0.27 (5.13-5.4) addi-
tional discounted QALYs and avoids 3.97 relapses, compared to OO. According
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